ArticleFrontiers in molecular neuroscience2026
Identification and validation of candidate biomarkers associated with mitochondria and 18 types of programmed cell death in trigeminal neuralgia: insights from transcriptome sequencing.
Article in Frontiers in molecular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trigeminal neuralgia (TN) is relatively prevalent among the elderly population. Mitochondria-regulated programmed cell death has been identified as an important mechanism in the pathogenesis of a series of diseases; however, its role in TN remains poorly understood. This study aimed to uncover mitochondria-related genes (MRGs) and programmed cell death-related genes (PCDRGs) implicated in TN and elucidate their potential mechanisms. Methods: The transcriptomic data of TN were obtained from clinical datasets, while MRGs and PCDRGs were retrieved from published literature. The processed transcriptome data were subjected to differential expression analysis and intersected with MRGs and PCDRGs to identify candidate genes. Subsequently, candidate biomarkers were further screened out via machine learning, and a nomogram was constructed. Additional analyses mainly included protein structure prediction, functional enrichment analysis, regulatory network analysis, drug prediction, and immune microenvironment analysis. Results: Among the 10 candidate genes, two candidate biomarkers (BCL2A1 and DBT) were employed to build a nomogram that exhibits favorable predictive performance. The protein structures of these biomarkers were predicted using the Human Protein Atlas (HPA) database, with a high level of confidence. Functional enrichment analysis revealed that these two candidate biomarkers might play a critical role in the progression of TN by regulating pathways such as "insulin signaling" and "Fc gamma R-mediated phagocytosis." Conclusion: This study identified two candidate biomarkers (BCL2A1 and DBT), which are linked to mitochondria and programmed cell death in TN, and explored their application value in clinical identification, offering novel research orientations for the diagnosis and treatment of TN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.